View the BioSpecifics
2013 Corporate Presentation
Originators in the development of injectable collagenase
|
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for 12 clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. |
Patient Discussion Forums
Forums are designed to enable patients and others concerned to interact with each other. Discussions on virtually any aspect of lipoma and Peyronie's disease are acceptable, however, please abide by the guidelines. |
Recent News
|